Evidence map›Paper›PMID 39470835›Full record

ArticlePediatric surgery international2024

Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models.

Ryo Sueyoshi, Junya Ishii, Susumu Yamada, Marumi Kawakami, Kenji Tanabe, Osamu Segawa

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryo SueyoshiDepartment of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan. sueyoshi.ryo@twmu.ac.jp.
Junya IshiiDepartment of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Susumu YamadaDepartment of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Marumi KawakamiTokyo Women's Medical University Institute for Comprehensive Medical Sciences, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Kenji TanabeTokyo Women's Medical University Institute for Comprehensive Medical Sciences, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Osamu SegawaDepartment of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.

Funding

Japan Society for the Promotion of Science JP21K08605
6 · The paper itself

Abstract

purposeThis study aimed to investigate the effectiveness of dipeptidyl peptidase IV inhibitors (DPP4-I) against liver damage, especially fibrosis and lipid accumulation, in a rat intestinal failure-associated liver disease (IFALD) model.

methodsSD rats were divided into two groups: the Control (n = 7; normal saline + IFALD model) and DPP4-I (n = 7; DPP4-I + IFALD model; short bowel syndrome (SBS) + total parenteral nutrition) groups. All rats were euthanized 21 days postoperatively to obtain tissue samples. Liver fibrosis was evaluated by Sirius Red and α-SMA staining. Liver damage was assessed using the steatosis, activity, and fibrosis score. Inflammation cytokines were examined by ELISA.

resultsThe survival rate was comparatively different, being 87.5% in the DPP4-I group and 70.0% in the Control group. Two rats of the Control group showed progressive liver fibrosis in the periportal area with fibrous streaks. Further, the mean area percentage of α-SMA immune-positive cells was significantly lower in the DPP4-I group than in the Control group. TGF-β levels were significantly lower in the DPP4-I group than in the Control group.

conclusionDPP4-I administration reduced liver fibrosis in IFALD, possibly by inhibiting DPP4-I-induced adipogenesis and suppressing TGF-β. These results may contribute to elucidating the mechanism of IFALD.

Indexed as

Dipeptidyl-Peptidase IV InhibitorsDisease Models, AnimalLipid MetabolismLiver CirrhosisRats, Sprague-DawleyAnimalsIntestinal DiseasesLiverMaleRatsDipeptidyl-Peptidase IV InhibitorsGLP-1IFALDLiver fibrosisShort bowel syndromeTGF-β

Identifiers

PMID39470835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.